Although tumor angiogenesis provides a promising target for the potential treatment of cancer, studies in mice and cancer patients have shown that anti-angiogenic therapies interfering with the VEGF pathway rarely induce long-lasting tumor responses [130], possibly due to the activation of VEGF-independent tumor vascularization [131]. This evidence concerns the gene VEGFA and cancer.